Altium Capital Management LLC Boosts Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Altium Capital Management LLC raised its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 150.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 714,000 shares of the biotechnology company's stock after acquiring an additional 429,000 shares during the quarter. Capricor Therapeutics makes up 2.8% of Altium Capital Management LLC's portfolio, making the stock its 10th biggest holding. Altium Capital Management LLC owned approximately 1.57% of Capricor Therapeutics worth $9,853,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Capricor Therapeutics by 51.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after buying an additional 37,868 shares in the last quarter. Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $276,000. JPMorgan Chase & Co. lifted its stake in shares of Capricor Therapeutics by 419.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after purchasing an additional 45,381 shares during the period. State Street Corp boosted its holdings in shares of Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Finally, Swiss National Bank purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at $930,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CAPR. HC Wainwright reissued a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Stock Up 14.3 %

Shares of CAPR traded up $1.71 during mid-day trading on Tuesday, reaching $13.63. 1,134,936 shares of the stock traded hands, compared to its average volume of 1,476,852. The firm has a market cap of $622.53 million, a price-to-earnings ratio of -12.79 and a beta of 4.65. The stock has a fifty day simple moving average of $12.27 and a 200 day simple moving average of $14.96. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. On average, equities research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.